Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.

Authors
Type
Published Article
Journal
OncoTargets and Therapy
1178-6930
Publisher
Dove Medical Press
Publication Date
Volume
5
Pages
177–184
Identifiers
DOI: 10.2147/OTT.S23267
PMID: 22973113
Source
Medline
Keywords
License
Unknown

Abstract

The purpose of this review article is to review recent advances in the treatment of advanced thymic epithelial tumors. These tumors are generally responsive to cytotoxic combination chemotherapy in the first-line setting. While newer agents have shown efficacy in the salvage setting, there is no one standard approach. A multitude of targeted agents have shown promise generally in case reports, though as of yet, nothing has shown consistent benefit. Because of the rarity of thymic epithelial tumors, clinical trial enrollment is difficult but nevertheless essential.

Statistics

Seen <100 times